Firm's vision is to harness power of microorganisms as a sustainable platform to produce proteins now derived from animals ...
Travere Therapeutics Stock (TVTX) is plummeting on news of a potential FDA delay for its kidney disease treatment ...
The U.S. Food and Drug Administration approved Fortress Biotech and Indian drugmaker Zydus Lifesciences' drug for children ...
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR ...
Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest ...
At a STAT event, veteran drug regulator Richard Pazdur, who left the FDA last month after 26 years, said that politics and ...
Can gene editing truly support smallholder farmers and help Indonesia achieve food sovereignty, or will it simply revive the ...
It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene ...
Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for ...
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 milli ...
Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy ...
Today’s lineup features a stark estimate of how Medicaid eligibility restrictions might lead to more cancer deaths, a look at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback